Antiviral activity of substituted salicylanilides - a review

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 11, 2011, Pages 956-967

  Kratky M ^a   Vinsova J ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Antiviral activity; Antiviral therapy; Nitazoxanide; Salicylamides; Salicylanilides

Indexed keywords

2 [[(2 PHENOXYETHOXY)CARBONOTHIOYL)(PHENYL]CARBAMOYL]PHENYL ACETATE; 2 HYDROXY 3,5 DIIODO N (4-PHENYLAMINO)PHENYL BENZAMIDE; 2 HYDROXY 4 (3 (2 HYDROXY 3,5 DINITROBENZAMIDO)PHENYL) 4 OXOBUT 2 ENOIC ACID; 3 [[3 (2,4 DIMETHYLPHENYLCARBOMOYL) 2 HYDROXYNAPHTHALEN 1 YL]DIAZENYL] 4 HYDROXYBENZENESULFONIC ACID; 3 TERT BUTYL 5 [2,4 DIOXOTETRAHYDROPYRIMIDINE 1(2H) YL) 2 HYDROXY N (4 (METHYLSULFONAMIDO)PHENYL]BENZAMIDE; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; INTEGRASE INHIBITOR; N (4 SULFAMOYLPHENYL)BENZAMIDE; N [4 [3 (4 ACETAMIDOPHENYL)THIOUREIDO] 2 CHLOROPHENYL] 1 HYDROXY 2 NAPHTAMIDE; N [4 [3 (5 CHLORO 2,4 DIMETHOXYPHENYL) THIOUREIDO]PHENYL0 2 HYDROXYBENZAMIDE; NICLOSAMIDE; NITAZOXANIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; RNA POLYMERASE; SALICYLANILIDE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA;

ANTIVIRAL ACTIVITY; BIOLOGICAL ACTIVITY; CHEMOTHERAPY; CORONAVIRUS; CORONAVIRUS INFECTION; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; INFLUENZA; INFLUENZA A; INFLUENZA VIRUS; NONHUMAN; PROTOZOAL INFECTION; REVIEW; ROTAVIRUS;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; ORTHOMYXOVIRIDAE; ROTAVIRUS; SALICYLANILIDES;

EID: 80052248027     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711797068382     Document Type: Review

References (138)

1. Vinšová, J.; Imramovský, A. Salicylanilidy - stále aktuální skupina s potenciální antibakteriální aktivitou. Cesk. Slov. Farm., 2004, 53, 294-299.
2. Wilson, D.F.; Ting, H.P.; Koppelman, M.S. Mechanism of Action of Uncouplers of Oxidative Phosphorylation. Biochemistry, 1971, 10, 2897-2902.
3. Terada, H.; Goto, S.; Yamamoto, K.; Takeuchi, I.; Hamada, Y.; Miyake, K. Structural requirements of salicylanilides for uncoupling activity in mitochondria: quantitative analysis of structureuncoupling relationships. Biochim. Biophys. Acta, 1988, 936, 504-512.
4. Kadenbach, B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim. Biophys. Acta, 2003, 1604, 77-94.
5. Brown, M.E.; Fitzner, J.N.; Stevens, T.; Chin, W.; Wright, C.D.; Boyce, J.P. Salicylanilides: Selective inhibitors of interleukin-12p40 production. Bioorg. Med. Chem., 2008, 16, 8760-8764.
6. Boyce, J.P.; Brown, M.E.; Chin, W.; Fitzner, J.N.; Paxton, R.J.; Shen, M.; Stevens, T.; Wolfson, M.F.; Wright, C.D. Identification of 14-3-3ζ by Chemical Affinity with Salicylanilide Inhibitors of Interleukin-12p40 Production. Bioconjugate Chem., 2008, 19, 1775-1784.
7. Sugita, A.; Ogawa, H.; Azuma, M.; Muto, S.; Honjo, A.; Yanagawa, H.; Nishioka, Y.; Tani, K.; Itai, A.; Sone, S. Antiallergic and Anti-Inflammatory Effects of a Novel IκB Kinase β Inhibitor, IMD-0354, in a Mouse Model of Allergic Inflammation. Int. Arch. Allergy Immunol., 2009, 148, 186-198.
8. Edwards, M.R.; Bartlett, N.W.; Clarke, D.; Birrell, M.; Belvisi, M.; Johnston, S.L. Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol. Ther., 2009, 121, 1-13.
9. Hardaker, A.L.; Bacon, A.M.; Carlson, K.; Roshak, A.K.; Foley, J.J.; Schmidt, D.B.; Buckley, P.T.; Comegys, M.; Panettieri, R.A.; Sarau, H.M.; Belmonte, K.E. Regulation of TNF-α and IFN-γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease. FASEB J., 2003, 17, 191.
10. Zhong, G.X.; Chen, L.L.; Li, J.; Hu, W.X.; Qi, M.Y. Synthesis and anti-inflammatory-analgesic activity of 2́,4́-difluoro-3- (carbamoyl)biphenyl-4-yl benzoates. Chin. Chem. Lett., 2008, 19, 1419-1422.
11. Biagi, G.; Giorgi, I.; Livi, O.; Scartoni, V.; Barili, P.L.; Calderone, V.; Martinotti, E. New 5-substituted-1-(2-hydroxybenzoyl)- benzotriazoles, potassium channel activators. IV. Farmaco, 2001, 56, 827-834.
12. Biagi, G.; Giorgi, I.; Livi, O.; Nardi, A.; Calderone, V.; Martelli, A.; Martinotti, E.; Salerni, OL. Synthesis and biological activity of novel substituted benzanilides as potassium channel activators. V. Eur. J. Med. Chem., 2004, 39, 491-498.
13. Calderone, V.; Coi, A.; Fiamingo, F.L.; Giorgi, I.; Leonardi, M.; Livi, O.; Martelli, A.; Martinotti, E. Structural modifications of benzanilide derivatives, effective potassium channel openers. X. Eur. J. Med. Chem., 2006, 41, 1421-1429.
14. Albuschat, R.; Löwe, W.; Weber, M.; Luger, P.; Jendrossek, V. 4- Anilinoquinazolines with LavendustinA subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties. Eur. J. Med. Chem., 2004, 39, 1001-1011.
15. Liechti, C.; Séquin, U.; Bold, G.; Furet, P.; Meyer, T.; Traxler, P. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. Eur. J. Med. Chem., 2004, 39, 11-26.
16. Deng, W.; Guo, Z.; Guo, Y.; Feng, Z.; Juany, Y.; Chu, F. Acryloylamino- salicylanilides as EGFR PTK inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 469-472.
17. Zhu, X.F.; Wang, J.S.; Cai, L.L.; Zeng, Y.X.; Yang, D. SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells. Cancer Sci., 2006, 97, 84-89.
18. Methot, J.L.; Chakravarty, P.K.; Chenard, M.; Close, J.; Cruz, J.C.; Dahlberg, W.K.; Fleming, J.; Hamblett, C.L.; Hamill, J.E.; Harrington, P.; Harsch, A.; Heidebrecht, R.; Hughes, B.; Jung, J.; Kenific, C.M.; Kral, A.M.; Meinke, P.T.; Middleton, R.E.; Ozerova, N.; Sloman, D.L.; Stanton, M.G.; Szewczak, A.A.; Tyagarajan, S.; Witter D.J.; Secristb, J.P.; Miller, TA. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18, 973-978.
19. Sun, Z.; Zhang, Y. Antituberculosis activity of certain antifungal and anthelmintic drugs. Tuber. Lung Dis., 1999, 79, 319-320.
20. Waisser, K.; Bureš, O.; Holý, P.; Kuneš, J.; Oswald, R.; Jirásková, L.; Pour, M.; Klimešová, V.; Kubicová, L.; Kaustová, J. Relationship between the Structure and Antimycobacterial Activity of Substituted Salicylanilides. Arch. Pharm. Pharm. Med. Chem., 2003, 1, 53-71.
21. Waisser, K.; Matyk, J.; Divišová, H.; Husáková, P.; Kuneš, J.; Klimešová, V.; Kaustová, J. The Oriented Development of Antituberculotics: Salicylanilides. Arch. Pharm. Chem. Life Sci., 2006, 339, 616-620.
22. Imramovský, A.; Vinšová, J.; Férriz, J.M.; Doležal, R.; Jampílek, J.; Kaustová, J.; Kunc, F. New Antituberculotics Originated from Salicylanilides with Promising In vitro Activity against Atypical Mycobacterial Strains. Bioorg. Med. Chem., 2009, 17, 3572-3579.
23. Imramovský, A.; Vinšová, J.; Férriz, J.M.; Buchta. V.; Jampílek, J. Salicylanilide esters of N-protected amino acids as novel antimicrobial agents. Bioorg. Med. Chem. Lett., 2009, 19, 348-351.
24. Vinsova, J.; Imramovsky, A.; Buchta, V.; Ceckova, M.; Dolezal, M.; Staud, F.; Jampilek, J.; Kaustova, J. Salicylanilide acetates: Synthesis and antibacterial evaluation. Molecules, 2007, 12, 1-12.
25. Férriz, J.M.; Vávrová, K.; Kunc, F.; Imramovský, A.; Stolaříková, J.; Vavšíková, E.; Vinšová, J. Salicylanilide carbamates: Antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains. Bioorg. Med. Chem., 2010, 18, 1054-1061
26. Krátký, M.; Vinšová, J.; Buchta, V.; Horvati, K.; Bösze, S.; Stolaříková, J. New amino acid esters of salicylanilides active against MDR-TB and other microbes. Eur. J. Med. Chem., 2010, 45, 6106-6113.
27. Pastor, L.; Garcia-Domenech, R.; Gálvez, J. New antifungals selected by molecular topology. Bioorg. Med. Chem. Lett., 1998, 8, 2577-2582.
28. Ienacu, I.M.C.; Lupea, A.X.; Hadaruga, D.; Hadaruga, N.; Popescu, I.M. The Antimicrobial Activity and Quantitative Structure - Biological Activity Relationships Evaluation of Some Novel 2- Hydroxybenzamide Derivatives. Rev. Chim., 2008, 59, 247-250.
29. Skála, P.; Macháček, M.; Vejsová, M.; Kubicová, L.; Kuneš. J.; Waisser, K. Synthesis and Antifungal Evaluation of Hydroxy-3- phenyl-2H-1,3-benzoxazine-2,4(3H)-diones and Their Thioanalogs. J. Heterocyclic Chem., 2009, 46, 873-880.
30. Macielag, M.J.; Demers, J.P.; Fraga-Spano, S.A.; Hlasta, D.J.; Johnson, S.G.; Kanojia, R.M.; Russel, R.K.; Sui, Z.H.; Weidner-Wells, M.A.; Werblood, H.; Foleno, B.D.; Goldschmidt, R.M.; Loeloff, M.J.; Webb, G.C.; Barrett, J.F. Substituted Salicylanilides as Inhibitors of Two-Component Regulatory Systems in Bacteria. J. Med. Chem., 1998, 41, 2939-2945.
31. Hlasta, D.J.; Demers, J.P.; Foleno, B.D.; Fraga-Spano, S.A.; Guan, J.; Hilliard, J.J.; Macielag, M.J.; Ohemeng, K.A.; Sheppard, C.M.; Sui, Z.H.; Webb, G.C.; Weidner-Wells, M.A.; Werblood, H.; Barrett, J.F. Novel inhibitors of bacterial two-component systems with Gram positive antibacterial activity: Pharmacophore identification based on the screening hit closantel. Bioorg. Med. Chem. Lett., 1998, 8, 1923-1928.
32. Hilliard, J.J.; Goldschmidt, R.M.; Licata, L.; Baum, E.Z.; Bush, K. Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems. Antimicrob. Agents Chemother., 1999, 43, 1693-1699.
33. Waisser, K.; Macháček, M.; Dostál, H.; Gregor, J.; Kubicová, L.; Klimešová, V.; Kuneš, J.; Palát, K.; Hladůvková, J.; Kaustová, J.; Molmann, U. Relationships between the Chemical Structure of Substances and their Antimycobacterial Activity Against Atypical Strains. Part 18. 3-Phenyl-2H-1,3-benzoxazine-2,4(3H)-diones and Isosteric 3-Phenylquinazoline-2,4-(1H,3H)-diones. Collect. Czech Chem. Commun., 1999, 24, 1902-1924.
34. Cui, Y.; Dang, Y.; Yang, Y.; Ji, R. Synthesis of novel oxazolidinone derivatives for antibacterial investigation. Curr. Sci., 2005, 89, 531-534.
35. De La Fuente, R.; Sonawane, N.D.; Arumainayagam, D.; Verkman, A.S. Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high-throughput screening. Br. J. Pharmacol., 2006, 149, 551-559.
36. Dahlgren, M.K.; Kauppi, A.M.; Olsson, I.M.; Linusson, A.; Elofsson, M. Design, Synthesis, and Multivariate Quantitative Structure-Activity Relationship of Salicylanilides - Potent Inhibitors of Type III Secretion in Yersinia. J. Med. Chem., 2007, 50, 6177-6188.
37. Ienacu, I.M.C.; Lupea, A.X.; Hadaruga, D.; Hadaruga, N.; Popescu, I.M. The Antimicrobial Activity and Quantitative Structure - Biological Activity Relationships Evaluation of Some Novel 2- Hydroxybenzamide Derivatives. Rev. Chim., 2008, 59, 247-250.
38. Kurita, M.; Shimauchi, T.; Kobayashi, M.; Atarashi, K.; Mori, K.; Tokura, Y. Induction of keratinocyte apoptosis by photosensitizing chemicals plus UVA. J. Dermatol. Sci., 2007, 45, 105-112.
39. Ronni, W.; Oumeish, Y.O. Photodermatoses. Clin. Dermatol., 1998, 16, 41-57.
40. Yamamoto, O.; Tokura, Y. Photocontact dermatitis and chloracne: two major occupational and environmental skin diseases induced by different actions of halogenated chemicals. J. Dermatol. Sci., 2003, 32, 85-94.
41. Victor, F.C.; Cohen, D.E.; Soter, N.A. A 20-year analysis of previous and emerging allergens that elicit photoallergic contact dermatitis. J. Am. Acad. Dermatol., 2010, 62, 605-610.
42. Ostrosky-Wegman, P.; García, G.; Montero, R.; Pérez Romero, B.; Alvarez Chacón, Cortinas de Nava, C. Susceptibility to genotoxic effects of niclosamide in human peripheral lymphocytes exposed in vitro and in vivo. Mutat. Res. Lett., 1986, 173, 81-87.
43. de la Torre, R.A.; de la Rúa Barceló, R.; Hernández, G.; Espinosa, J.J.; Cortinas de Nava, C. Genotoxic effects of niclosamide in Aspergillus nidulans. Mutat. Res.-Genet. Tox., 1989, 222, 337-341.
44. Espinosa-Aguirre, J.J.; Reyes, R.E.; de Nava, C.C. Mutagenic activity of 2-chloro-4-nitroaniline and 5-chlorosalicylic acid in Salmonella typhimurium - 2 possible metabolites of niclosamide. Mut. Res., 1991, 264, 139-145.
45. Girl, A.K.; Adhikari, N.; Khan, K.A. Comparative genotoxicity of six salicylic acid derivatives in bone marrow cells of mice. Mutat. Res., 1996, 370, 1-9.
46. Donya, S.M.; Hassan, E.E. Clastogenic Effects of the Fasciolicides Closantel and Nitroxynil on Mice Somatic and Germ Cells. Cytologia, 2007, 72, 29-36.
47. Randad, R.S.; Lubkowska, L.; Silva, A.M.; Guerin, D.M.A.; Gulnik, S.V.; Yu, B.; Erickson, J.W. Structure-Based Design of Achiral, Nonpeptidic Hydroxybenzamide as a Novel P2/P2' Replacement for the Symmetry-Based HIV Protease Inhibitors. Bioorg. Med. Chem., 1996, 4, 1471-1480.
48. Keating, M.R. Antiviral Chemotherapy. Princip. Med. Biol., 1998, 9, 529-549.
49. Jerome, K.R. The road to new antiviral therapies. Clin. Appl. Immun. Rev., 2005, 5, 65-76.
50. Richman, D.D. Antiviral drug resistance. Antiviral Res., 2006, 71, 117-121.
51. Griffiths, P.D. A perspective on antiviral resistence. J. Clin. Virol., 2009, 46, 3-8.
52. Haagmans, B.L.; Osterhaus, A.D.M.E. Coronaviruses and their therapy. Antiviral Res., 2006, 71, 397-403.
53. Wu, C.J.; Jan, J.T.; Chen, C.M.; Hsieh, H.P.; Hwang, D.R.; Liu, H.W.; Liu, C.Y.; Huang, H.W.; Chen, S.C.; Hong, C.F.; Lin, R.K.; Chao, Y.S.; Hsu, J.T.A. Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide. Antimicrob. Agents Chemother., 2004, 48, 2693-2696.
54. Wen, C.C.; Kuo, Y.H.; Jan, J.T.; Liang, P.H.; Wang, S.Y.; Liu, H.G.; Lee, C.K.; Chang, S.T.; Kuo, C.J.; Lee, S.S.; Hou, C.C.; Hsiao, P.W.; Chien, S.C.; Shyur, L.F.; Yang, N.S. Specific Plant Terpenoids and Lignoids Possess Potent Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus. J. Med. Chem., 2007, 50, 4087-4095.
55. Zhang, X.W.; Yap, Y.L. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg. Med. Chem., 2004, 12, 2517-2521.
56. Shie, J.J.; Fang, J.M.; Kuo, C.J.; Kuo, T.H.; Liang, P.H.; Huang, H.J.; Yang, W.B.; Lin, C.H.; Chen, J.L.; Wu, Y.T.; Wong, C.H. Discovery of Potent Anilide Inhibitors against the Severe Acute Respiratory Syndrome 3CL Protease. J. Med. Chem., 2005, 48, 4469-4473.
57. Zhu, P.J.; Hobson, J.P.; Southall, N.; Qiu, C.; Thomas, C.J.; Lu, J.; Inglese, J.; Zheng, W.; Leppla, S.H.; Bugge, T.H.; Austin, C.P; Liu, S. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorg. Med. Chem., 2009, 17, 5139-5145.
58. Chang, Y.W.; Yeh, T.K.; Lin, K.T.; Chen, W.C.; Yao, H.T.; Lan, S.J.; Wu, Y.S.; Hsieh, H.P.; Chen, C.M.; Chen, C.T. Pharmacokinetics of Anti-SARS-CoV Agent Niclosamide and Its Analogs in Rats. J. Food Drug Anal., 2006, 14, 329-333.
59. Pyrc, K.; Bosch, B.J.; Berkhout, B.; Jebbink, M.F.; Dijkman, R.; Rottier, P.; van der Hoek, L. Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle. Antimicrob. Agents Chemother., 2006, 50, 2000-2008.
60. Li, H.C.; Wang, C.; Sanchez, T.; Tan, Y.; Jiang, C.; Neamati, N.; Zhao, G. Amide-containing diketoacids as HIV-1 integrase inhibitors: Synthesis, structure-activity relationship analysis, and biological activity. Bioorg. Med. Chem., 2009, 17, 2913-2919.
61. Ray, S.; Fatima, Z.; Saxena, A. Drugs for AIDS. Mini-Rev. Med. Chem., 2010, 10, 147-161.
62. Chen, I.J.; Neamati, N.; Nicklaus, M.C.; Orr, A.; Anderson, L.; Barchi, J.J.; Kelley, J.A.; Pommier, Y.; MacKerell, A.D. Identification of HIV-1 Integrase Inhibitors via Three-Dimensional Database Searching Using ASV and HIV-1 Integrases as Targets. Bioorg. Med. Chem., 2000, 8, 2385-2398.
63. Zhao, G.; Wang, C.; Liu, C.; Lou, H. New Developments in Diketo-Containing Inhibitors of HIV-1 Integrase. Mini-Rev. Med. Chem., 2007, 7, 707-725.
64. Neamati, N.; Hong, H.; Owen, J.M.; Sunder, S.; Winslow, H.E.; Christensen, J.L.; Zhao, H.; Burke, T.R.; Milne, G.W.A.; Pommier, Y. Salicylhydrazine-Containing Inhibitors of HIV-1 Integrase: Implication for a Selective Chelation in the Integrase Active Site. J. Med. Chem., 1998, 41, 3202-3209.
65. Marchand, C.; Beutler, J.A.; Wamiru, A.; Budihas, S.; Möllmann, U.; Heinisch, L.; Mellors, J.W.; Le Grice, S.F.; Pommier, Y. Madurahydroxylactone Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and RNase H. Antimicrob. Agents Chemother., 2008, 52, 361-364.
66. Ranise, A.; Spallarossa, A.; Schenone, S.; Bruno, O.; Bondavalli, F.; Vargiu, L.; Marceddu, T.; Mura, M.; La Colla, P.; Pani, A. Design, Synthesis, SAR, and Molecular Modeling Studies of Acylthiocarbamates: A Novel Series of Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors Structurally Related to Phenethylthiazolylthiourea Derivatives. J. Med. Chem., 2003, 46, 768-781.
67. Tummino, P.J.; Harvey, P.J.; McQuade, T.; Domagala, J.; Gogliotti, R.; Sanchez, J.; Song, Y.; Hupe, D. The Human Immunodeficiency Virus Type 1 (HIV-1) Nucleocapsid Protein Zinc Ejection Activity of Disulfide Benzamides and Benzisothiazolones: Correlation with Anti-HIV and Virucidal Activities. Antimicrob. Agents Chemother., 1997, 41, 394-400.
68. Gordon, C.P.; Keller, P.A. Control of Hepatitis C: A Medicinal Chemistry Perspective. J. Med. Chem., 2005, 48, 1-20.
69. Wagner, R.; Tufano, M.D.; Stewart, K.D.; Rockway, T.W.; Randolph, J.T.; Pratt, J.K.; Motter, C.E.; Maring, C.J.; Longenecker, K.L.; Liu, Y.; Liu, D.; Krueger, A.C.; Kati, W.M.; Hutchinson, D.K.; Huang, P.P.; Flentge, C.A.; Donner, P.L.; Degoey, D.A.; Betebenner, D.A.; Barnes, D.M.; Chen, S.; Franczyk II, T.S.; Gao, Y.; Haight, A.R.; Hengeveld, J.E.; Henry, R.F.; Kotecki, B.J.; Lou, X.; Sarris, K.; Zhang, G.G.Z. Uracil or thymine derivative for treating hepatitis C. Patent WO 2009/039127, March 26, 2009.
70. Kronenberger, B.; Zeuzem, S. Current and future treatment options for HCV. Ann. Hepatol., 2009, 8, 103-112.
71. Kim, S.S.; Peng, L.F.; Lin, W.; Choe, W.; Sakamoto, N.; Schreiber, S.L.; Chung, R.T. A Cell-Based, High-Throughput Screen for Small Molecule Regulators of Hepatitis C Virus Replication. Gastroenterology, 2007, 132, 311-320.
72. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel hepatitis C virus protease inhibitors: 2,4,6-trihydroxy, 3-nitro-benzamide derivatives. Antiviral Chem. Chemother., 1997, 8, 541-544.
73. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel hepatitis C virus protease inhibitors: 2,4,6- trihydroxy, 3-nitro-benzamide derivatives. Antiviral Chem. Chemother., 1998, 9, 186. (errata)
74. Kakiuchi, N.; Komoda, Y.; Komoda, K.; Takeshita, N.; Okada, S.; Tani, T.; Shimotohno, K. Non-peptide inhibitors of HCV serine proteinase. FEBS Lett., 1998, 421, 217-220.
75. Liu, Y.; Donner, P.L.; Pratt, J.K.; Jiang, W.W.; Ng, T.; Gracias, V.; Baumeister, S.; Wiedeman, P.E.; Traphagen, L.; Warrior, U.; Maring, C.; Kati, W.M.; Djuric, S.W.; Molla, A. Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase. Bioorg. Med. Chem. Lett., 2008, 18, 3173-3177.
76. Jääskeläinen, A.J.; Moilanen, K.; Bühler, S.; Lappalainen, M.; Vapalahti, O.; Vaheri, A.; Piiparinen, H. Serological microarray for detection of HSV-1, HSV-2, VZV, and CMV antibodies. J. Virol. Methods, 2009, 160, 167-171.
77. Bloom, J.D.; Curran, K.J.; Digrandi, M.J.; Dushin, R.G.; Lang, S.A.; Norton, E.B.; Ross, A.A.; O'Hara, B.M. Alpha-methylbenzylcontaining thiourea derivatives containing a phenylenediamine group, useful as inhibitors of herpes viruses. Patent WO 00/34260, June 15, 2000.
78. Bloom, J.D.; Curran, K.J.; Digrandi, M.J.; Dushin, R.G.; Lang, S.A.; Norton, E.B.; Ross, A.A.; O'Hara, B.M. Benzamidecontaining aryl thiourea derivatives useful as inhibitors of herpes viruses. Patent WO 00/34238, June 15, 2000.
79. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors. Drug Discov. Today, 1997, 2, 487-498.
80. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M.C.; Mazumder, A.; Zhao, H.; Burke, T.R.; Pommier, Y, Milne, G.W.A. Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching. J. Med. Chem., 1997, 40, 930-936.
81. Zhao, H.; Neamati, N.; Sunder, S.; Hong, H.; Wang, S.; Milne, G.W.A.; Pommier, Y.; Burke, TR. Hydrazide-Containing Inhibitors of HIV-1 Integrase. J. Med. Chem., 1997, 40, 937-941.
82. Hong, H.; Neamati, N.; Winslow, H.E.; Christensen, J.L.; Orr, A.; Pommier, Y.; Milne, G.W.A. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chem. Chemother., 1998, 9, 461-472.
83. Takashiro, E.; Watanabe, T.; Nitta, T.; Kasuya, A.; Miyamoto, S.; Ozawa, Y.; Yagi, R.; Nishigaki, T.; Shibayama, T.; Nakagawa, A.; Iwamoto, A.; Yabe, Z. Structure-Activity Relationship of HIV-1 Protease Inhibitors Containing AHPBA. Part III: Modification of P2 Site. Bioorg. Med. Chem., 1998, 6, 595-604.
84. Neamati, N.; Lin, Z.; Karki, R.G.; Orr, A.; Cowansage, K.; Strumberg, D.; Pais, G.C.G.; Voigt, J.H.; Nicklaus, M.C.; Winslow, H.E.; Zhao, H.; Turpin, J.A.; Yi, J.; Skalka, A.M.; Burke, T.R.; Pommier, Y. Metal-Dependent Inhibition of HIV-1 Integrase. J. Med. Chem., 2002, 45, 5661-5670.
85. Cotelle, P. Patented HIV-1 Integrase Inhibitors (1998-2005). Recent Pat. Antiinfect. Drug Discov., 2006, 1, 1-15.
86. Dayam, R.; Sanchez, T.; Clement, O.; Shoemaker, R.; Sei, S.; Neamati, N. βDiketo Acid Pharmacophore Hypothesis. 1. Discovery of a Novel Class of HIV-1 Integrase Inhibitors. J. Med. Chem., 2005, 48, 111-120.
87. Pfefferkorn, J.A.; Nugent, R.; Gross, R.J.; Greene, M.; Mitchell, M.A.; Reding, M.T.; Funk, L.A.; Anderson, R.; Wells, P.A.; Shelly, J.A.; Anstadt, R.; Finzel, B.C.; Harris, M.S.; Kilkuskie, R.E.; Kopta, L.A.; Schwende, F.J. Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the northern region of (2Z)-2- benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid. Bioorg. Med. Chem. Lett., 2005, 15, 2812-2818.
88. Luo, G.X.; Colonno, R.; Krystal, M. Characterization of a Hemagglutinin- Specific Inhibitor of Influenza A Virus. Virology, 1996, 226, 66-76.
89. Steinmetzer, T. Strategien für die Entwicklung neuartiger Grippemittel. Pharm. Unserer Zeit, 2011, 40, 160-168.
90. Combrink, K.D.; Gulgeze, H.B.; Yu, KL.; Pearce, B.C.; Trehan, A.K.; Wei, J.M.; Deshpande, M.; Krystal, M.; Torri, A.; Luo, G.X.; Cianci, C.; Danetz, S.; Tiley, L.; Meanwell, N.A. Salicylamide inhibitors of influenza virus fusion. Bioorg. Med. Chem. Lett., 2000, 10, 1649-1652.
91. Deshpande, M.S.; Wei, J.M.; Luo, G.X.; Cianci, C.; Danetz, S.; Torri, A.; Tiley, L.; Krystal, M.; Yu, K.L.; Huang, S.; Gao, Q.; Meanwell, N.A. An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. Bioorg. Med. Chem. Lett., 2001, 11, 2393-2396.
92. Yu, K.-L.; Torri, A.F.; Luo, G.X.; Cianci, C.; Grant-Young, K.; Danetz, S.; Tiley, L.; Krystal, M.; Meanwell, N.A. Structure- Activity Relationships for a Series of Thiobenzamide Influenza Fusion Inhibitors Derived from 1,3,3-Trimethyl-5-hydroxycyclohexylmethylamine. Bioorg. Med. Chem. Lett., 2002, 12, 3379-3382.
93. Lagoja, I.M.; De Clercq, E. Anti-InfluenzaVirus Agents: Synthesis and Mode of Action. Med. Res. Rev., 2008, 28, 1-38.
94. Luo, G.X.; Torri, A.; Harte, W.E.; Danetz, S.; Cianci, C.; Tiley, L.; Day, S.; Mullaney, D.; Yu, K.L.; Ouellet, C.; Dextraze, P.; Meanwell, N.; Colonno, R.; Krystal, M. Molecular Mechanism Underlying the Action of a Novel Fusion Inhibitor of Influenza A Virus. J. Virol., 1997, 71, 4062-4070.
95. Krug, R.M.; Aramini, J.M. Emerging antiviral targets for influenza A virus. Trends Pharmacol. Sci., 2009, 30, 269-277.
96. Basu, D.; Walkiewicz, M.P.; Frieman, M.; Baric, R.S.; Auble, D.T.; Engel, D.A. Novel influenza virus NS1 antagonists block replication and restore innate immune function. J. Virol., 2009, 83, 1881-1891.
97. Rollinger, J.M.; Schmidtke, M. TheHuman Rhinovirus: Human- Pathological Impact,Mechanisms of Antirhinoviral Agents, and Strategies forTheir Discovery. Med. Res. Rev., 2010, 31, 42-92.
98. Küçükgüzel, G.; Kocatepe, A.; De Clercq, E.; Şahin, F.; Güllüce, M. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur. J. Med. Chem., 2006, 41, 353-359.
99. Santoro, M.G.; Ciucci, A.; Gianferretti, P.; Belardo, G.; La Frazia, S.; Carta, S.; Rossignol, J.F. Thiazolides: A New Class of Broad- Spectrum Antiviral Drugs Targeting Virus Maturation. Antiviral Res., 2007, 74, A31.
100. Rossignol, J.F. Thiazolides: a new class of antiviral drugs. Exp. Opin. Drug Metabol. Toxicol., 2009, 5, 667-674.
101. Mederacke, I.; Wedemeyer, H. Nitazoxanide for the treatment of chronic hepatitis C. New opportunities but new challenges? Ann. Hepatol., 2009, 8, 166-168.
102. Keeffe, E.B.; Rossignol, J.F. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J. Gastroenterology, 2009, 15, 1805-1808.
103. Rossignol, J.F.; Kabil, S.M.; El-Gohary, Y.; Elfert, A.; Keeffe, E.B. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther., 2008, 28, 574-580.
104. Korba, B.; Abigail, M.; Marc, A.; Rossignol, J.F. Nitazoxanide is an Effective Antiviral Agent Against Both HBV and HCV replication in vitro. Antiviral Res., 2007, 74, A40.
105. Bacon, B.; Shiffman, M.; Lim, J.; Berman, A.; Rustgi, V.; Keeffe, E. Phase 2 randomized, doubleblind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR. J. Hepatol., 2009, 50, S381.
106. Shiffman, M.; Ahmed, A.; Jacobson, I. Phase 2 randomized, double- blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis. J. Hepatol., 2009, 50, S385-S386.
107. Rossignol, J.F.; Elfert, A.; Keeffe, E.B. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (peginf) plus NTZ for treatment of chronic hepatitis C: final report. Hepatology, 2008, 48, 1132-1133.
108. Rossignol, J.F.; Korba, B.E.; Kabil, S.M. Nitazoxanide in treating chronic hepatitis C: in vitro activity and a clinical case series. Gastroenterology, 2006, 130, A841.
109. Rossignol, J.F.; Elfert, A.; El-Gohary, Y.; Keeffe, E.B. Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin. Gastroenterology, 2009, 136, 856-862.
110. Rossignol. J.F.; Keeffe, E.B. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol., 2008, 3, 539-545.
111. Korba, B.E.; Montero, A.B.; Farrar, K.; Gaye, K.; Mukerjee, S.; Ayers, M.S.; Rossignol, J.F. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res., 2008, 77, 56-63.
112. Elazar, M.; Liu, M.; McKenna, S.A.; Liu, P.; Gehring, E.A.; Puglisi, J.D.; Rossignol, J.F.; Glenn, J.S. The Anti-Hepatitis C Agent Nitazoxanide Induces Phosphorylation of Eukaryotic Initiation Factor 2 alpha Via Protein Kinase Activated by Double-Stranded RNA Activation. Gastroenterology, 2009, 137, 1827-1835.
113. Korba, B.; Glenn, J.; Elazar, M.; Rossignol, J.F. A Role for Nitazoxanide in Combination with STAT-C Agents for Inhibition of HCV Replication and the Potential for the Prevention of Viral Resistance. Antiviral Res., 2009, 82, A20.
114. Korba, B.E.; Elazar, M.; Lui, P.; Rossignol, J.F.; Glenn, J.S. Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide. Antimicrob. Agents Chemother., 2008, 52, 4069-4071.
115. Teran, C.G.; Teran-Escalera, C.N.; Villarroel, P. Nitazoxanide vs. probiotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int. J. Infect. Dis., 2009, 13, 518-523.
116. Rossignol, J.F.; El-Gohary, Y.M. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment. Pharmacol. Ther., 2006, 24, 1423-1430.
117. Rossignol, J.F.; Abu-Zekry, M.; Hussein, A.; Santoro, M.G. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet, 2006, 368, 124-129.
118. Rossignol, J.F.; La Frazia, S.; Chiappa, L.; Ciucci, A.; Santoro, M.G. Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level. J. Biol. Chem., 2009, 284, 29798-29808.
119. Gilles, H.M.; Hoffman, P.S. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol., 2002, 18, 95-97.
120. Anderson, V.R.; Curran, M.P. Nitazoxanide. A Review of its Use in the Treatment of Gastrointestinal Infections. Drugs, 2007, 67, 1947-1967.
121. Hoffman, P.S.; Sisson, G.; Croxen, M.A.; Welch, K.; Harman, W.D.; Cremades, N.; Morash, M.G. Antiparasitic Drug Nitazoxanide Inhibits the Pyruvate Oxidoreductases of Helicobacter pylori, Selected Anaerobic Bacteria and Parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother., 2007, 51, 868-876.
122. Fox, L.M.; Saravolatz, L.D. Nitazoxanide: A New Thiazolide Antiparasitic Agent. Clin. Infect. Dis., 2005, 40, 1173-1180.
123. Stadelmann, B.; Scholl, S.; Muller, J.; Hemphill, A. Application of an in vitro drug screening assay based on the release of phosphoglucose isomerase to determine the structure-activity relationship of thiazolides against Echinococcus multilocularis metacestodes. J. Antimicrob. Chemother., 2010, 65, 512-519.
124. Adagu, I.S.; Nolder, D.; Warhurst, D, Rossignol, J.F. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother., 2006, 50, 103-111.
125. Sisson, G.; Goodwin, A.; Raudonikiene, A.; Hughes, N.J.; Mukhopadhyay, A.K.; Berg, D.E.; Hoffman, P.S. Enzymes Associated with Reductive Activation and Action of Nitazoxanide, Nitrofurans, and Metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother., 2002, 46, 2116-2123.
126. Ballard, T.E., Wang, X., Olekhnovich, I., Koerner, T., Seymour, C., Hoffman, P.S., Macdonald, T.L. Biological Activity of Modified and Exchanged 2-Amino-5-Nitrothiazole Amide Analogues of Nitazoxanide, Bioorg. Med. Chem. Lett., 2010, 20, 3537-3539.
127. Pankuch, G.A.; Appelbaum, P.C. Activities of Tizoxanide and Nitazoxanide Compared to Those of Five Other Thiazolides and Three Other Agents against Anaerobic Species. Antimicrob. Agents Chemother., 2006, 50, 1112-1117.
128. Musher, D.M; Logan, N.D.; Bressler, A.M.; Johnson, D.P.; Rossignol, J.F. Nitazoxanide in the Treatment of Clostridium difficile Disease. Gastroenterology, 2008, 134, A-669.
129. Musher, D.M.; Logan, N.; Hamill, R.J.; DuPont, H.L.; Lentnek, A.; Gupta, A.; Rossignol, J.F. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis., 2006, 43, 421-427.
130. Musher, D.M.; Logan, N.; Mehendiratta, V.; Melgarejo, N.A.; Garud, S.; Hamill, R.J. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob. Chemother., 2007, 59, 705-710.
131. Callan, R.J.; Ashton, L.V.; Goehring, L.S. Nitazoxanide and tizoxanide inhibit EHV-1 and influenza type A virus replication in vitro. J. Vet. Intern. Med., 2008, 22, 738-738.
132. Lappin, M.R.; Clark, M.; Scorza A.V. Treatment of healthy Gardia spp. positive dogs with fenbendazole or nitazoxanide. J. Vet. Intern. Med., 2008, 22, 778-778.
133. Lappin, M.R.; Spindel, M.; Riggenbach, L. Infectious agent prevalence rates in dogs with diarrhea and response to administration of fenbendazole or nitazoxanide. J. Vet. Intern. Med., 2008, 22, 779.
134. MacKay, R.J. Equine Protozoal Myeloencephalitis: Treatment, Prognosis, and Prevention. Clin. Techniques Equine Pract., 2006, 5, 9-16.
135. M.; Stettler, R.; Moores, S.L.; Pidathala, C.; Muller, N.; Stachulski, A.; Berry, N.G.; Rossignol, J.F.; Hemphill, A. In vitro Efficacies of Nitazoxanide and Other Thiazolides against Neospora caninum Tachyzoites Reveal Antiparasitic Activity Independent of the Nitro Group. Antimicrob. Agents Chemother., 2005, 49, 3715-3723.
136. Lanata, C.F.; Franco, M. Nitazoxanide for rotavirus diarrhoea? Lancet, 2006, 368, 100-101.
137. Darling, J.M.; Fried, M.W. Nitazoxanide: Beyond Parasites toward a Novel Agent for Hepatitis C. Gastroenterology, 2009, 136, 760-763.
138. Babu, T.A.; Venkatesh, C. Nitazoxanide use in Rota Viral Diarrhea. Cure or Controversy? Indian J. Pediatr., 2010, 77, 1450.